Tauro-β-muricholic Acid sodium (T-βMCA sodium), a endogenous metabolite, is a competitive and reversible farnesoid X receptor (FXR) antagonist, with an IC 50 of 40 μM.
性状
Solid
IC50 & Target[1][2]
IC50: 40 μM (FXR)
体外研究(In Vitro)
T-βMCA sodium inhibits FXR reporter activity in the CRC cell line HT29 (EC50 ~10 μM).T-βMCA sodium dose-dependently increases WNT signaling in HT29 and HCT116 cells.T-βMCA sodium induces proliferation and DNA damage in Lgr5 cells. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
T-βMCA sodium (400 mg/kg; i.g.; twice a week; for 6 weeks) can effectively recapitulate the ability of HFD to promote CRC progression.
T-βMCA sodium treatment also significantly increases levels of serum cytokines, including IFN-γ, IL-6, and IL-17. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
-20°C, stored under nitrogen In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
参考文献
[1]. Sayin SI, et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 2013 Feb 5;17(2):225-35.[2]. Wahlstr?m A, et al. Induction of farnesoid X receptor signaling in germ-free mice colonized with a human microbiota. J Lipid Res. 2017 Feb;58(2):412-419.
溶解度数据
In Vitro: DMSO : 10 mg/mL (18.60 mM; Need ultrasonic and warming)配制储备液